Role of epidermal growth factor receptor and the HER-2 gene in hormone refractory prostate cancer

Kang Su Cho, Dong Jun Kim, Joong Shik Lee, Namhoon Cho, Kyeongmee Park, Won Sik Ham, Youngdeuk Choi

Research output: Contribution to journalArticle

Abstract

Purpose: Amplification and mutation of the epidermal growth factor receptor (EGFR) and HER-2 genes were analyzed in the tissues of hormone refractory prostate cancer (HRPC) patients. Materials and Methods: Gene amplifications of the EGFR and HER-2 gene were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of the EGFR gene and exons 19 and 20 of the HER-2 gene. The amplifications and mutations were compared with the clinicopathologic features. Results: Gene amplification of the EGFR gene was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient with a hormone refractory status had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer, but they were not associated with the ductal type. No significant correlation was found between mutation change and the hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (p=0.017). There were no HER-2 gene amplifications or mutations found in any of the samples. Conclusions: EGFR gene mutation and amplification occurred frequently in these advanced prostate cancer cases, but EGFR mutations do not appear to play a significant role in the hormone refractory pathway. However, EGFR gene mutation is closely associated with the time to convert to HRPC.

Original languageEnglish
Pages (from-to)24-30
Number of pages7
JournalKorean Journal of Urology
Volume49
Issue number1
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

erbB-2 Genes
Epidermal Growth Factor Receptor
Prostatic Neoplasms
Hormones
erbB-1 Genes
Mutation
Gene Amplification
Exons
Sequence Deletion
Fluorescence In Situ Hybridization

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Cho, Kang Su ; Kim, Dong Jun ; Lee, Joong Shik ; Cho, Namhoon ; Park, Kyeongmee ; Ham, Won Sik ; Choi, Youngdeuk. / Role of epidermal growth factor receptor and the HER-2 gene in hormone refractory prostate cancer. In: Korean Journal of Urology. 2008 ; Vol. 49, No. 1. pp. 24-30.
@article{07c71122f800458b9a3272dd3c838aba,
title = "Role of epidermal growth factor receptor and the HER-2 gene in hormone refractory prostate cancer",
abstract = "Purpose: Amplification and mutation of the epidermal growth factor receptor (EGFR) and HER-2 genes were analyzed in the tissues of hormone refractory prostate cancer (HRPC) patients. Materials and Methods: Gene amplifications of the EGFR and HER-2 gene were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of the EGFR gene and exons 19 and 20 of the HER-2 gene. The amplifications and mutations were compared with the clinicopathologic features. Results: Gene amplification of the EGFR gene was observed in 6 (30{\%}) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient with a hormone refractory status had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer, but they were not associated with the ductal type. No significant correlation was found between mutation change and the hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (p=0.017). There were no HER-2 gene amplifications or mutations found in any of the samples. Conclusions: EGFR gene mutation and amplification occurred frequently in these advanced prostate cancer cases, but EGFR mutations do not appear to play a significant role in the hormone refractory pathway. However, EGFR gene mutation is closely associated with the time to convert to HRPC.",
author = "Cho, {Kang Su} and Kim, {Dong Jun} and Lee, {Joong Shik} and Namhoon Cho and Kyeongmee Park and Ham, {Won Sik} and Youngdeuk Choi",
year = "2008",
month = "1",
day = "1",
doi = "10.4111/kju.2008.49.1.24",
language = "English",
volume = "49",
pages = "24--30",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "1",

}

Role of epidermal growth factor receptor and the HER-2 gene in hormone refractory prostate cancer. / Cho, Kang Su; Kim, Dong Jun; Lee, Joong Shik; Cho, Namhoon; Park, Kyeongmee; Ham, Won Sik; Choi, Youngdeuk.

In: Korean Journal of Urology, Vol. 49, No. 1, 01.01.2008, p. 24-30.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of epidermal growth factor receptor and the HER-2 gene in hormone refractory prostate cancer

AU - Cho, Kang Su

AU - Kim, Dong Jun

AU - Lee, Joong Shik

AU - Cho, Namhoon

AU - Park, Kyeongmee

AU - Ham, Won Sik

AU - Choi, Youngdeuk

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: Amplification and mutation of the epidermal growth factor receptor (EGFR) and HER-2 genes were analyzed in the tissues of hormone refractory prostate cancer (HRPC) patients. Materials and Methods: Gene amplifications of the EGFR and HER-2 gene were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of the EGFR gene and exons 19 and 20 of the HER-2 gene. The amplifications and mutations were compared with the clinicopathologic features. Results: Gene amplification of the EGFR gene was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient with a hormone refractory status had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer, but they were not associated with the ductal type. No significant correlation was found between mutation change and the hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (p=0.017). There were no HER-2 gene amplifications or mutations found in any of the samples. Conclusions: EGFR gene mutation and amplification occurred frequently in these advanced prostate cancer cases, but EGFR mutations do not appear to play a significant role in the hormone refractory pathway. However, EGFR gene mutation is closely associated with the time to convert to HRPC.

AB - Purpose: Amplification and mutation of the epidermal growth factor receptor (EGFR) and HER-2 genes were analyzed in the tissues of hormone refractory prostate cancer (HRPC) patients. Materials and Methods: Gene amplifications of the EGFR and HER-2 gene were analyzed by fluorescence in situ hybridization (FISH) with direct sequencing. Studies were performed on 10 patients; tissues were sampled at the time of initial diagnosis and after the conversion to HRPC (a total of 20 tissue samples). Direct sequencing was performed on exons 18-24 of the EGFR gene and exons 19 and 20 of the HER-2 gene. The amplifications and mutations were compared with the clinicopathologic features. Results: Gene amplification of the EGFR gene was observed in 6 (30%) out of 20 samples. A total of six EGFR mutations in exons 18 and 19 were detected in three pairs of tissues (three patients). One patient with a hormone refractory status had a novel deletion mutation in EGFR exon 19. EGFR mutations were associated with the acinar type of prostate cancer, but they were not associated with the ductal type. No significant correlation was found between mutation change and the hormone sensitive or refractory status. However, the time to convert to HRPC was significantly shorter in the patients with a mutation in the EGFR gene (p=0.017). There were no HER-2 gene amplifications or mutations found in any of the samples. Conclusions: EGFR gene mutation and amplification occurred frequently in these advanced prostate cancer cases, but EGFR mutations do not appear to play a significant role in the hormone refractory pathway. However, EGFR gene mutation is closely associated with the time to convert to HRPC.

UR - http://www.scopus.com/inward/record.url?scp=38949151881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949151881&partnerID=8YFLogxK

U2 - 10.4111/kju.2008.49.1.24

DO - 10.4111/kju.2008.49.1.24

M3 - Article

AN - SCOPUS:38949151881

VL - 49

SP - 24

EP - 30

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 1

ER -